Skip to main content

Table 5 Predictive value of each status

From: The usefulness of 18F-FDG PET/CT for assessing methotrexate-associated lymphoproliferative disorder (MTX-LPD)

  CR (n = 9) non-CR (n = 6) p-value
Duration of MTX (month) 50 (7–172) 81 (40–234) 0.19
Dose of MTX (mg/week) 8.0 (4.0–16.0) 9.0 (6.0–16.0) 0.14
Number of sites 5 (1–99) 3 (1–41) 0.30
SUVmax 9.2 (2.8–47.1) 13.9 (0–24.9) 0.21
WBMTV (ml) 26.6 (0–362.6) 22.7 (0–250.1) 0.36
WBTLG (ml) 111.6 (0–2180.9) 152.1 (0–1052.1) 0.25
sIL-2R (U/ml) 758 (310–3157) 795 (259–5861) 0.16
  1. CR complete response, MTX methotrexate, sIL-2R soluble interleukin-2 receptor, SUVmax maximum of standardized uptake value, WBMTV whole body metabolic tumor volume, WBTLG whole body total legion glycolysis